Order Article Reprints

Barkhordar M, Ahmadvand M, Sharifi Aliabadi L, Noorani SS, Bagheri Amiri F, Janbabai G, Sorouri R, Asadi Milani M, Vaezi M. Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines. 2023; 11(1):117. https://doi.org/10.3390/vaccines11010117

Barkhordar, Maryam, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, Seied Saeid Noorani, Fahimeh Bagheri Amiri, Ghasem Janbabai, Rahim Sorouri, Mona Asadi Milani, and Mohammad Vaezi. 2023. "Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial" Vaccines 11, no. 1: 117. https://doi.org/10.3390/vaccines11010117

Barkhordar, M., Ahmadvand, M., Sharifi Aliabadi, L., Noorani, S. S., Bagheri Amiri, F., Janbabai, G., Sorouri, R., Asadi Milani, M., & Vaezi, M. (2023). Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines, 11(1), 117. https://doi.org/10.3390/vaccines11010117